New developments in traveler's diarrhea

Gastroenterology and Hepatology

Volumn 7, Issue 2, 2011, Pages 88-95

  De La Cabada Bauche, Javier ^a   DuPont, Herbert L ^a,b,c  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Azithromycin; Enterotoxigenic escherichia coli; Irritable bowel syndrome; Rifaximin; Travelers diarrhea

Indexed keywords

AZITHROMYCIN; BISMUTH SALICYLATE; CHOLERA TOXIN B SUBUNIT; CIPROFLOXACIN; ESCHERICHIA COLI VACCINE; LEVOFLOXACIN; LOPERAMIDE; PROBIOTIC AGENT; RIFAXIMIN;

AEROMONAS; AFRICA; ANTIBIOTIC RESISTANCE; ASIA; CAMPYLOBACTER; DISABILITY; ESCHERICHIA COLI; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; INFECTION PREVENTION; INFECTION RISK; LABORATORY TEST; MORBIDITY; NECROTOXIGENIC ESCHERICHIA COLI; NOROVIRUS; PLESIOMONAS; REVIEW; SALMONELLA; SELF MEDICATION; SHIGELLA; SINGLE DRUG DOSE; SOUTH AND CENTRAL AMERICA; TRAVELLER DIARRHEA; VACCINATION; VIBRIO;

EID: 79952800273     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Greenwood Z, Black J, Weld L, et al. Gastrointestinal infection among international travelers globally. J Travel Med. 2008;15:221-228. (Pubitemid 352020245)
2. Kean BH. The diarrhea of travelers to Mexico. Summary of five-year study. Ann Intern Med. 1963;59:605-614.
3. Rowe B, Taylor J, Bettelheim KA. An investigation of traveler's diarrhoea. Lancet. 1970;1:1-5.
4. Wanger AR, Murray BE, Echeverria P, Mathewson JJ, DuPont HL. Enteroinvasive Escherichia coli in travelers with diarrhea. J Inject Dis. 1988;158:640-642.
5. Meraz IM, Jiang ZD, Ericsson CD, et al. Enterotoxigenic Escherichia coli and diffusely adherent E. coli as likely causes of a proportion of pathogen-negative travelers' diarrhea - a PCR-based study. J Travel Med. 2008;15:412-418.
6. Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers' diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg. 2009;80:609-614.
7. Porter CK, Riddle MS, Tribble DR, et al. The epidemiology of travelers' diarrhea in Incirlik, Turkey: a region with a predominance of heat-stabile toxin producing enterotoxigenic Escherichia coli. Diagn Microbiol Infect Dis. 2010;66:241-247.
8. Jiang ZD, Lowe B, Verenkar MP, et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Inject Dis. 2002;185:497-502. (Pubitemid 34142812)
9. Koo HL, Ajami NJ, Jiang ZD, et al. Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico. J Clin Microbiol. 2010;48:1673-1676.
10. Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med. 2006;354: 119-130. (Pubitemid 43076709)
11. Vlieghe ER, Jacobs JA, Van Esbroeck M, Koole O, Van Gompel A. Trends of norfloxacin and erythromycin resistance of Campylobacter jejuni/Campylobacter coli isolates recovered from international travelers, 1994 to 2006. J Travel Med. 2008;15:419-425.
12. Riddle MS, Sanders JW, Putnam SD, Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers (US military and similar populations): a systematic review. Am J Trop Med Hyg. 2006;74:891-900. (Pubitemid 46774414)
13. Houf K, Stephan R. Isolation and characterization of the emerging foodborn pathogen Arcobacter from human stool. Microbiol Methods. 2007;68:408-413. (Pubitemid 46149957)
14. Jiang ZD, DuPont HL, Brown EL, et al. Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic Bacteroides fragilis and Arcobacter species. J Clin Microbiol. 2010;48:1417-1419.
15. Teague NS, Srijan A, Wongstitwilairoong B, et al. Enteric pathogen sampling of tourist restaurants in Bangkok, Thailand. J Travel Med. 2010;17:118-123.
16. Nakano V, Gomes DA, Arantes RM, Nicoli JR, Avila-Campos MJ. Evaluation of the pathogenicity of the Bacteroides fragilis toxin gene subtypes in gnotobiotic mice. Curr Microbiol. 2006;53:113-117. (Pubitemid 44165838)
17. Scars CL, Islam S, Saha A, et al. Association of enterotoxigenic Bacteroides fragilis infection with inflammatory diarrhea. Clin Infect Dis. 2008;47:797-803.
18. Ko G, Garcia C, Jiang ZD, et al. Noroviruses as a cause of travelers' diarrhea among students from the United States visiting Mexico. J Clin Microbiol. 2005;43:6126-6129. (Pubitemid 43100672)
19. Ajami N, Koo H, Darkoh C, et al. Characterization of norovirus-associated travelers' diarrhea. Clin Infect Dis. 2010;51:123-130.
20. Apelt N, Hartberger C, Campe H, Löscher T. The prevalence of norovirus in returning international travelers with diarrhea. BMC Infect Dis. 2010;10:131.
21. Chapin AR, Carpenter CM, Dudley WC, et al. Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler's diarrhea. J Clin Microbiol. 2005;43:1112-1117. (Pubitemid 40364926)
22. Widdowson MA, Cramer EH, Hadley L, Bresce JS. Outbreaks of acute gastroenteritis on cruise ships and on land: identification of a predominant circulating strain of norovirus United States, 2002. J Infect Dis. 2004;190:27-36. (Pubitemid 38858401)
23. Kornylo K, Kim DK, Widdowson MA, Turabelidze G, Averhoff FM. Risk of norovirus transmission during air travel. J Travel Med. 2009;16:349-351.
24. Widdowson MA, Glass R, Monroe S, et al. Probable transmission of norovirus on an airplane. JAMA. 2005;293:1859-1860.
25. Wichro E, Hoelzl D, Krause R, Bertha G, Reinthaler F, Wenisch C. Microsporidiosis in travel-associated chronic diarrhea in immune-competent patients. Am J Trop Med Hyg. 2005;73:285-287. (Pubitemid 41278700)
26. Müller A, Bialek R, Kämper A, Fätkenheuer G, Salzberger B, Franzen C. Detection of microsporidia in travelers with diarrhea. J Clin Microbiol. 2001;39:1630-1632. (Pubitemid 32275481)
27. Huang P, Weber JT, Sosin DM, et al. The first reported outbreak of diarrheal illness associated with Cyclospora in the United States. Ann Intern Med. 1995;123:409-414.
28. Herwaldt BL, Ackers ML. An outbreak in 1996 of cyclosporiasis associated with imported raspberries. The Cyclospora Working Group. N Engl J Med. 1997;336:1548-1556.
29. Ramírez-Olivencia G, Herrero MD, Subirats M, Rivas González P, Puente S. Cyclospora cayetanensis outbreak in travelers to Cuba [in Spanish]. Enferm Infecc Microbiol Clin. 2008;26:558-560.
30. Puente S, Morente A, García-Benayas T, Subirats M, Gascón J, González-Lahoz JM. Cyclosporiasis: a point source outbreak acquired in Guatemala. J Travel Med. 2006;13:334-337. (Pubitemid 44722264)
31. Karanis P, Kourenti C, Smith H. Waterborne transmission of protozoan parasites: a worldwide review of outbreaks and lessons learnt. J Water Health. 2007;5:1-38. (Pubitemid 46415958)
32. Shlim DR, Hoge CW, Rajah R, Rabold JG, Echeverria P. Is Blastocystis hominis a cause of diarrhea in travelers? A prospective controlled study in Nepal. Clin Infect Dis. 1995;21:97-101.
33. Kozicki M, Steffen R, Schar M. 'Boil it, cook it, peel it or forget it': does this rule prevent travellers' diarrhoea? Int J Epidemiol. 1985;14:169-172.
34. Shlim DR. Looking for evidence that personal hygiene precautions prevent travelers diarrhea. Clin Infect Dis. 2005;41:S531-S535. (Pubitemid 41691582)
35. Alon D, Shitrit P, Chowers M. Risk behaviors and spectrum of diseases among elderly travelers: a comparison of younger and older adults. J Travel Med. 2010;17:250-255.
36. Jiang ZD, Okhuysen PC, Guo DC, et al. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J Infect Dis. 2003;188:506-511. (Pubitemid 37011801)
37. Flores J, DuPont HL, Lee SA, et al. Influence of host interleukin-10 polymorphisms on development of traveler's diarrhea due to HEAT-labile enterotoxin-producing Escherichia coli in travelers from the United States who are visiting Mexico. Clin Vaccine Immunol. 2008;15:1194-1198.
38. Mohamed JA, DuPont HL, Jiang ZD, et al. A novel single-nuclcotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. Clin Infect Dis. 2007;44:945-952. (Pubitemid 46452059)
39. Mohamed JA, DuPont HL, Jiang ZD, et al. A single-nucleoride polymorphism in the gene encoding osteoprotegerin, an anti-inflammatory protein produced in response to infection with dtarrheagenic Escherichia coli, is associated with an increased risk of nonsecretory bacterial diarrhea in North American travelers to Mexico. J Infect Dis. 2009;199:477-485.
40. Huang P, Farkas T, Marionneau S, et al. Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. J Infect Dis. 2003;188:19-31. (Pubitemid 36829738)
41. Hutson AM, Airaud F, LePendu J, Estes MK, Atmar RL. Norwalk virus infection associates with secretor status genotyped from sera. J Med Virol. 2005;77:116-120. (Pubitemid 41076487)
42. Marionneau S, Airaud F, Bovin NV, Pendu JL, Ruvoen-Clouet N. Influence of the combined ABO, FUT2, and FUT3 polymorphism on susceptibility to norwalk virus attachment. J Infect Dis. 2005;192:1071-1077. (Pubitemid 41266806)
43. Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis. 2002;185:1335-1337. (Pubitemid 34439142)
44. Steffen R, Tornieporth N, Clemens SA, et al. Epidemiology of travelers' diarrhea: details of a global survey. J Travel Med. 2004;11:231-237.
45. Tuteja AK, Talley NJ, Gelman SS, et al. Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA. Dig Dis Sci. 2008;53:271-276. (Pubitemid 350265680)
46. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol. 2004;99:1774-1778. (Pubitemid 39237507)
47. Stermer E, Lubezky A, Potasman I, Paster E, Lavy A. Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis. 2006;3:898-901. (Pubitemid 44435519)
48. Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol. 2007;42:41-47. (Pubitemid 46140363)
49. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six-year follow up study. Gut. 2002;51:410-413.
50. Törnblom H, Holmvall P, Svenungsson B, Lindberg G. Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults. Clin Gastroenterol Hepatol. 2007;5:461-464. (Pubitemid 46575368)
51. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM; Walkerton Health Study Investigators. Eight-year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59:605-611.
52. Thornley JP, Jenkins D, Neal K, Wright T, Brough J, Spiller RC. Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis. 2001;184:606-609. (Pubitemid 32783552)
53. DuPont HL, Galler G, Garcia-Torres F, Dupont AW, Greisinger A, Jiang ZD. Travel and travelers' diarrhea in patients with irritable bowel syndrome. Am J Trop Med Hyg. 2010;82:301-305.
54. DuPont HL, Ericsson CD, Mathewson JJ, DuPont MW. Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study. Antimicrob Agents Chemother. 1992;36:87-91.
55. Taylor DN, Bourgeois AL, Ericsson CD, et al. A randomized, double-blind, mulricenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg. 2006;74:1060-1066. (Pubitemid 351627416)
56. DuPont HL Jiang ZD, Belkind-Gerson J, et al. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol. 2007;5:451-456. (Pubitemid 46575371)
57. Ericsson CD, DuPont HL, Mathewson JJ. Optimal dosing of ofloxacin with loperamide in the treatment of non-dysenteric travelers' diarrhea. J Travel Med. 2001;8:207-209. (Pubitemid 33143863)
58. Ericsson CD, DuPont HL Okhuysen PC, Jiang ZD, DuPont MW. Loperamide plus azithromycin more effectively treats travelers' diarrhea in Mexico than azithromycin alone. J Travel Med. 2007;14:312-319. (Pubitemid 47460252)
59. Sack DA, Kaminsky DC, Sack RB, et al. Prophylactic doxycycline for travelers' diarrhea. Results of a prospective double-blind study of Peace Corps volunteers in Kenya. N Engl J Med. 1978;298:758-763.
60. Rademaker CM, Hoepelman IM, Wolfhagen MJ, Beumer H, Rozenberg-Arska M, Verhoef J. Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers' diarrhea. Eur J Clin Microbiol Infect Dis. 1989;8:690-694. (Pubitemid 19207157)
61. Gorbach S, Edelman R. Travelers diarrhea: National Institutes of Health Consensus Development Conference. Rev Infect Dis. 1986;8:S109-S233.
62. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005;142:805-812. (Pubitemid 40664039)
63. Martinez-Sandoval F, Ericsson CD, Jiang ZD, et al. Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico. J Travel Med. 2010;17:111-117.
64. DuPont HL, Sullivan P, Evans DG, et al. Prevention of travelers diarrhea (emporiatric enteritis). Prophylactic administration of subsalicylate bismuth. JAMA. 1980;243:237-241.
65. DuPont HL, Ericsson CD, Johnson PC, et al. Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate. JAMA. 1987;257:1347-1350. (Pubitemid 17024853)
66. Graham DY, Estes MK, Gentry LO. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers. Gastroenterology. 1983;85:1017-1022. (Pubitemid 13007791)
67. Hilton E, Kolakowski P, Singer C, Smith M. Efficacy of Lactobacillus GG as a diarrheal preventive in travelers. J Travel Med. 1997;4:41-43. (Pubitemid 27200255)
68. Kollaritsch H, Holst H, Grobara P, Wiedermann G. Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo-controlled double-blind study. Fortschr Med. 1993;111:152-156.
69. Oksanen PJ, Salminen S, Saxelin M, et al. Prevention of travellers' diarrhoea by Lactobacillus GG. Ann Med. 1990;22:53-56.
70. DuPont HL, Ericsson CD, Farthing MJ, et al. Expert review of the evidence base for prevention of travelers' diarrhea. J Travel Med. 2009;16:149-160.
71. Bulmer E. A survey of tropical diseases as seen in the Middle East. Trans R Soc Trop Med Hyg. 1944;37:225-242.
72. DuPont HL, Haynes GA, Pickering LK, et al. Diarrhea of travelers to Mexico. Relative susceptibility of United States and Latin American students attending a Mexican University. Am J Epidemiol. 1977;105:37-41. (Pubitemid 8020093)
73. Brown MR, DuPont HL, Sullivan PS. Effects of duration of exposure on diarrhea due to enterotoxigenic Escherichia coli in travelers from the United States to Mexico. J Infect Dis. 1982;145:582. (Pubitemid 12158350)
74. Sack DA, Harris JR, Chakraborty J, et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis. 1988;158:372-377.
75. Peltola H, Siitonen A, Kyronseppa H, et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet. 1991;338:1285-1289.
76. Glenn GM, Villar CP, Flyer DC, et al. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect Immun. 2007;75:2163-2170. (Pubitemid 46744302)
77. McKenzie R, Bourgeois AL, Freeh SA, et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine. 2007;25:3684-3691. (Pubitemid 46584755)
78. Frech SA, DuPont HL, Bourgeois AL, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomized, double-blind, placebo-controlled field trial. Lancet. 2008;371:2019-2025.
79. McKenzie R, Bourgeois AL, Engstrom F, et al. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults. Infect Immun. 2006;74:994-1000. (Pubitemid 43185535)
80. Lundkvist J, Steffen R, Jönsson B. Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea. J Travel Med. 2009;16:28-34.